Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Deep Functional Phenotyping of the ALA Lung Health Cohort

Lead Sponsor:

Johns Hopkins University

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

American Lung Association

Conditions:

Lung Diseases

Eligibility:

All Genders

25-35 years

Brief Summary

The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, en...

Detailed Description

The parent Lung Health Cohort (LHC) study will leverage the national infrastructure of the American Lung Association's (ALA) Airways Clinical Research Centers (ACRC) to form the first national cohort ...

Eligibility Criteria

Inclusion

  • Age 25-35 years at the time of the baseline examination
  • Able to read and understand English or Spanish
  • Has a social security number
  • Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination.
  • Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.
  • Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant

Exclusion

  • Severe asthma, which is defined as any of the following:
  • Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) or high dose inhaled corticosteroid \[ICS\] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS.
  • OR
  • 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
  • One asthma hospitalization in the past 12 months
  • History of any chronic lung disease other than asthma including but not limited to chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
  • Current pregnancy
  • History of cancer other than non-melanoma skin cancer
  • Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
  • Inability to comply with study procedures, including
  • Inability or unwillingness to provide informed consent
  • Inability to perform study measurements
  • Inability to be contacted by phone (via calls and/or text messaging) or email
  • Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
  • Institutionalization

Key Trial Info

Start Date :

February 12 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 30 2026

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT06177717

Start Date

February 12 2024

End Date

July 30 2026

Last Update

February 20 2025

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

University of Alabama

Birmingham, Alabama, United States, 35294

2

University of California, Los Angeles

Los Angeles, California, United States, 90095

3

National Jewish Health

Denver, Colorado, United States, 80206

4

Nemours Children's Jacksonville

Jacksonville, Florida, United States, 32207